Literature DB >> 16950019

Chapter 7: Achievements and limitations of cervical cytology screening.

Henry C Kitchener1, Philip E Castle, J Thomas Cox.   

Abstract

This chapter reviews the contribution of cervical cytology, what makes it successful, the management of screen positives and how technological advances may affect its use in the future. Cervical screening has saved hundreds of thousands of lives but has not been available to women in the poorest countries. In countries where wide coverage has been achieved and quality assurance is in place, incidence and death rates have fallen by over 50% even though cervical cytology is logistically complex. The management of high-grade cervical intraepithelial neoplasia (CIN) is very effective, but low-grade cytological abnormalities require care to avoid over-treatment. The increasing rate of human papillomavirus (HPV) testing and the prospect of prophylactic vaccination will change the way cervical cytology is used, possibly giving way to HPV testing as the primary test in secondary prevention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16950019     DOI: 10.1016/j.vaccine.2006.05.113

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  69 in total

1.  Factors associated with time to colposcopy after abnormal Pap testing in HIV-infected women.

Authors:  Amy S Baranoski; Elizabeth A Stier
Journal:  J Womens Health (Larchmt)       Date:  2011-12-05       Impact factor: 2.681

2.  Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice.

Authors:  Walter Kinney; Barbara Fetterman; J Thomas Cox; Thomas Lorey; Tracy Flanagan; Philip E Castle
Journal:  Gynecol Oncol       Date:  2011-01-26       Impact factor: 5.482

3.  International Image Concordance Study to Compare a Point-of-Care Tampon Colposcope With a Standard-of-Care Colposcope.

Authors:  Jenna L Mueller; Elizabeth Asma; Christopher T Lam; Marlee S Krieger; Jennifer E Gallagher; Alaattin Erkanli; Roopa Hariprasad; J S Malliga; Lisa C Muasher; Bariki Mchome; Olola Oneko; Peyton Taylor; Gino Venegas; Anthony Wanyoro; Ravi Mehrotra; John W Schmitt; Nimmi Ramanujam
Journal:  J Low Genit Tract Dis       Date:  2017-04       Impact factor: 1.925

4.  Controlling cervical cancer.

Authors:  Maurizio Bonati; Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer.

Authors:  Philip E Castle; Ana C Rodríguez; Robert D Burk; Rolando Herrero; Allan Hildesheim; Diane Solomon; Mark E Sherman; Jose Jeronimo; Mario Alfaro; Jorge Morales; Diego Guillén; Martha L Hutchinson; Sholom Wacholder; Mark Schiffman
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

6.  Psychiatric morbidity and cervical cancer screening: a retrospective population-based case-cohort study.

Authors:  Michael Ouk; Jodi D Edwards; Jessica Colby-Milley; Alexander Kiss; Walter Swardfager; Marcus Law
Journal:  CMAJ Open       Date:  2020-03-10

7.  Optimizing technology for cervical cancer screening in high-resource settings.

Authors:  Lyndsay A Richardson; Joseph Tota; Eduardo L Franco
Journal:  Expert Rev Obstet Gynecol       Date:  2011-05

8.  How protective is cervical cancer screening against cervical cancer mortality in developing countries? The Colombian case.

Authors:  Luz Angela Chocontá-Piraquive; Nelson Alvis-Guzman; Fernando De la Hoz-Restrepo
Journal:  BMC Health Serv Res       Date:  2010-09-16       Impact factor: 2.655

9.  Development and characterization of the cobas human papillomavirus test.

Authors:  Arundhati Rao; Stephen Young; Henry Erlich; Sean Boyle; Mark Krevolin; Rita Sun; Raymond Apple; Catherine Behrens
Journal:  J Clin Microbiol       Date:  2013-02-27       Impact factor: 5.948

10.  Program spending to increase adherence: South African cervical cancer screening.

Authors:  Jeremy D Goldhaber-Fiebert; Lynette A Denny; Michelle De Souza; Louise Kuhn; Sue J Goldie
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.